Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.85 USD
Change Today -0.07 / -2.40%
Volume 591.3K
ATHX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 12:12 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

athersys inc (ATHX) Snapshot

Open
$2.92
Previous Close
$2.92
Day High
$2.94
Day Low
$2.82
52 Week High
04/2/14 - $3.50
52 Week Low
04/28/14 - $1.08
Market Cap
227.9M
Average Volume 10 Days
2.1M
EPS TTM
$-0.35
Shares Outstanding
80.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ATHERSYS INC (ATHX)

Related News

No related news articles were found.

athersys inc (ATHX) Related Businessweek News

No Related Businessweek News Found

athersys inc (ATHX) Details

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company’s lead platform product, MultiStem cell therapy, an allogeneic stem cell product, which is in Phase II clinical trials for the treatment of ischemic stroke and inflammatory bowel disease (IBD); and that has completed Phase I clinical trial for the treatment of acute myocardial infarction and hematopoietic stem cell transplant/graft-versus-host disease. It is also developing MultiStem cell therapy for the treatment of acute respiratory distress syndrome. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. In addition, the company is involved in identifying and developing small molecule compounds with potential applications in indications, including obesity; related metabolic conditions, such as diabetes; and neurological indications consisting of schizophrenia. It has license agreement with Chugai Pharmaceutical Co., Ltd. to develop MultiStem cell therapy for ischemic stroke in Japan, as well as collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat IBD; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; and collaboration with Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets produced compound screening and development. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

57 Employees
Last Reported Date: 03/12/15
Founded in 1995

athersys inc (ATHX) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: $599.8K
President, Chief Operating Officer and Secret...
Total Annual Compensation: $464.5K
Co-Founder, Chief Scientific Officer, Executi...
Total Annual Compensation: $462.0K
Principal Financial Officer and Vice Presiden...
Total Annual Compensation: $283.3K
Executive Vice President of Regenerative Medi...
Total Annual Compensation: $381.6K
Compensation as of Fiscal Year 2014.

athersys inc (ATHX) Key Developments

Athersys, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Athersys, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, total revenues were $0.2 million compared to $0.9 million for the same period in 2013, reflecting a decrease in contract revenues and grant revenue. Net loss was $6.6 million, compared to $9.8 million for the same period of 2013. The difference reflects the impact of a $4.2 million positive variance in the fair value of warrant liabilities, the $0.7 million decrease in revenues, the $0.5 million increase in research and development expenses, and a $0.2 million increase in income tax benefits related to refundable foreign tax credits. Loss from operations was $7.1 million against $5.8 million a year ago. Loss before income taxes was $6.8 million against $9.8 million a year ago. Basic and diluted net loss per share was $0.08 against $0.15 a year ago. For the year, total revenues were $1.6 million compared to $2.4 million for 2013, reflecting a $0.5 million decrease in contract revenues and a $0.3 million decrease in grant revenues. Net loss was $22.1 million, compared to $30.7 million in 2013. The difference reflects a $12.9 million non-cash increase in the change in the fair value of warrant liabilities, the $0.8 million decrease in revenues, the $3.7 million increase in combined research and development and general and administrative expenses, and a $0.2 million increase in income tax benefits related to refundable foreign tax credits. Cash used in operating activities was $25.8 million and $22.8 million in 2014 and 2013, respectively. Loss from operations was $29.0 million against $24.5 million a year ago. Loss before income taxes was $22.3 million against $30.7 million a year ago. Diluted net loss per share was $0.31 against basic and diluted net loss per share of $0.53 a year ago.

Athersys, Inc. Presents at 12th Annual BIO Asia International Conference, Mar-24-2015 01:00 PM

Athersys, Inc. Presents at 12th Annual BIO Asia International Conference, Mar-24-2015 01:00 PM. Venue: Grand Hyatt Hotel, Tokyo, Japan.

Athersys, Inc. and Chugai Pharmaceutical Co., Ltd. Announce Partnership and License Agreement to Develop MultiStem(R) Cell Therapy for Ischemic Stroke in Japan

Athersys, Inc. and Chugai Pharmaceutical Co. Ltd. announced a partnership and license agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan. Ischemic stroke represents a priority disease area in Japan, given the high healthcare burden of the condition and the expected increase in incidence associated with Japan's aging population. Athersys' proprietary cell therapy product, MultiStem, is currently being evaluated in a Phase 2 clinical study for ischemic stroke in the United States and Europe, and Athersys has begun preparations for clinical development in Japan, including engagement with the Japanese Health Authority. Chugai is a leading research-based pharmaceutical company with strengths in biotechnology products, and brings to the collaboration substantial expertise and experience in late-stage development and commercialization in Japan. As part of the collaboration, Chugai will be responsible for the development and commercialization of MultiStem for ischemic stroke in Japan, and Athersys will have responsibility for product supply. Under the financial terms of the agreement, Athersys will receive an up-front cash payment of $10 million from Chugai and would receive additional payments as the program is further advanced. Athersys is eligible to receive milestone payments from Chugai of up to $45 million upon the successful achievement of certain development and regulatory milestones, and sales milestones of up to 17.5 billion Yen (approximately $150 million based on the current exchange rate). Athersys would also receive from Chugai tiered, double-digit royalties on any net sales, as well as payments for product supplied to Chugai. In Athersys' ongoing Phase 2 clinical study, it is evaluating the administration of MultiStem cell therapy to patients who have suffered an ischemic stroke. Based on preclinical research to date, administration of MultiStem has shown significant benefits through several mechanisms, including reduction of inflammation and immune system modulation in the ischemic area, and the protection and rescue of damaged or injured cells, including neuronal tissue. Athersys is treating patients one to two days after the stroke has occurred, in contrast to thrombolytic tPA treatment, which is limited to the first three to four hours following the stroke. Preclinical studies have demonstrated that administration of a single dose of MultiStem therapy, even one week after a stroke, provides significant and durable improvements relative to controls. Enrollment in Athersys' double-blind, placebo-controlled trial is complete, and interim safety and initial efficacy results following the ninety-day patient data are expected to be announced in April 2015, following analysis and receipt of the unblinded clinical data.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATHX:US $2.85 USD -0.0701

ATHX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $4.97 USD -0.0299
Cytori Therapeutics Inc $1.19 USD 0.00
Ocata Therapeutics Inc $6.15 USD +0.0099
Pluristem Therapeutics Inc $2.82 USD -0.01
StemCells Inc $1.03 USD +0.042
View Industry Companies
 

Industry Analysis

ATHX

Industry Average

Valuation ATHX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 139.5x
Price/Book 10.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 128.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ATHERSYS INC, please visit www.athersys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.